The CCHCR1 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human CCHCR1 gene. This product provides a heterogeneous pool of HEK293T cells harboring gene disruptions at the CCHCR1 locus, creating a loss-of-function model for studying its roles in centrosome biology and cell cycle regulation.
The parental HEK293T cell line is derived from human embryonic kidney cells transformed with adenovirus 5 DNA and stably expresses the SV40 large T antigen. These cells are widely recognized for their high transfection efficiency and robust protein expression capabilities, making them a preferred host for viral packaging, signal transduction studies, and large-scale biochemical analyses.
CCHCR1 encodes a centrosomal and midbody protein that regulates cell cycle progression and cytoskeletal dynamics. It interacts with HSPA8 and centrosomal proteins, and its function is integrated with the IL-17 signaling pathway. Upon IL-17 binding to IL-17RA, the adaptor ACT1 recruits TRAF6, leading to NF-??B activation and transcription of inflammatory targets. CCHCR1 loss disrupts these networks, altering the expression of downstream targets such as RAC1, cyclin B1, and p21, thereby affecting centrosome duplication and proliferation.
In HEK293T cells, knockout of CCHCR1 provides a well-controlled system to investigate centrosome integrity and cell cycle dysregulation associated with hyperproliferative skin disorders like psoriasis. The ease of genetic manipulation and the well-characterized signaling landscape of HEK293T cells enable detailed dissection of IL-17/NF-??B pathway contributions to pathological cell division. This model helps elucidate how disruptions in centrosomal proteins can lead to aberrant signaling and proliferative phenotypes.
These polyclonal knockout cells are suitable for a broad range of applications, including mechanistic studies of psoriasis pathogenesis, centrosome duplication processes, and cell cycle control. They can be used in functional assays such as immunofluorescence staining for ??-tubulin to visualize centrosomal abnormalities, flow cytometry for cell cycle analysis, BrdU incorporation assays to measure proliferation, western blotting for cyclin B1 and p21 quantification, and NF-??B luciferase reporter assays to monitor pathway activity. For further information, please contact Ascent Research.
